Rankings
▼
Calendar
MDGL Q1 2020 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
MDGL
Madrigal Pharmaceuticals, Inc.
$10B
Q1 2020 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$38M
Net Income
-$36M
EPS (Diluted)
$-2.34
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$31M
Free Cash Flow
-$31M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$411M
Total Liabilities
$26M
Stockholders' Equity
$385M
Cash & Equivalents
$67M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
-$28,000
+100.0%
Operating Income
-$38M
-$18M
-109.8%
Net Income
-$36M
-$15M
-139.6%
← FY 2020
All Quarters
Q2 2020 →